Abstract
Background:
To analyze peripheral non-cutaneous T-cell lymphomas (NC-TCL) and to test the significance of the IPI.
Patients and methods:
Twenty-nine consecutive patients diagnosed with NC-TCL according to the REAL classification.
Results:
At diagnosis were common: B symptoms (21%), stage III/IV (55%), high LDH level (55%) and extranodal involvement (79%). Twelve (48%) patients achieved complete remission. The IPI identified groups of patients with different response to therapy and survival.
Conclusions:
NC-TCL with high or high-intermediate IPI had a short survival if treated with CHOP.
Publication types
-
English Abstract
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Lymphoma, T-Cell, Peripheral / drug therapy
-
Lymphoma, T-Cell, Peripheral / mortality
-
Lymphoma, T-Cell, Peripheral / pathology*
-
Lymphoma, T-Cell, Peripheral / radiotherapy
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Prognosis
-
Prospective Studies
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone